These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 36695773)

  • 1. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease.
    Han AL; Lee HK
    Metabolites; 2022 Jul; 12(7):. PubMed ID: 35888788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of non-invasive indicators in the screening of metabolic dysfunction-associated fatty liver disease: a cross-sectional study among Uighurs in rural Xinjiang.
    Guo Y; Hu Y; Yang J; Ma R; Zhang X; Guo H; Wang X; Li Y; Peng X; Zhang S; He J; Guo S
    Eur J Med Res; 2023 Dec; 28(1):555. PubMed ID: 38042816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome.
    Vassilatou E; Lafoyianni S; Vassiliadi DA; Ioannidis D; Paschou SA; Mizamtsidi M; Panagou M; Vryonidou A
    Maturitas; 2018 Oct; 116():1-7. PubMed ID: 30244768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of five hepatic steatosis algorithms in metabolic-associated fatty liver disease: A population based study.
    Liu Y; Liu S; Huang J; Zhu Y; Lin S
    J Gastroenterol Hepatol; 2022 May; 37(5):938-945. PubMed ID: 35174539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease.
    Motamed N; Sohrabi M; Ajdarkosh H; Hemmasi G; Maadi M; Sayeedian FS; Pirzad R; Abedi K; Aghapour S; Fallahnezhad M; Zamani F
    World J Gastroenterol; 2016 Mar; 22(10):3023-30. PubMed ID: 26973398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic ability using fatty liver and metabolic markers for metabolic-associated fatty liver disease stratified by metabolic/glycemic abnormalities.
    Okada A; Yamada G; Kimura T; Hagiwara Y; Yamaguchi S; Kurakawa KI; Nangaku M; Yamauchi T; Matsuyama Y; Kadowaki T
    J Diabetes Investig; 2023 Mar; 14(3):463-478. PubMed ID: 36566480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation and comparison of simple tools to screen for nonalcoholic fatty liver disease in Chinese community population.
    Zhang L; Zhang M; Wang M; Wang M; Zhang R; Wang H; Zhang W; Ding Y; Wang J
    Eur J Gastroenterol Hepatol; 2022 Aug; 34(8):865-872. PubMed ID: 35802528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the appropriate cutoff points for anthropometric indices and their relationship with cardio-metabolic indices to predict the risk of metabolic associated fatty liver disease.
    Hosseini SA; Alipour M; Sarvandian S; Haghighat N; Bazyar H; Aghakhani L
    BMC Endocr Disord; 2024 Jun; 24(1):79. PubMed ID: 38834991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The lipid accumulation product is a powerful tool to diagnose metabolic dysfunction-associated fatty liver disease in the United States adults.
    Li H; Zhang Y; Luo H; Lin R
    Front Endocrinol (Lausanne); 2022; 13():977625. PubMed ID: 36407325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population.
    Cai J; Lin C; Lai S; Liu Y; Liang M; Qin Y; Liang X; Tan A; Gao Y; Lu Z; Wu C; Huang S; Yang X; Zhang H; Kuang J; Mo Z
    Lipids Health Dis; 2021 Oct; 20(1):145. PubMed ID: 34706716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential screening indicators for early diagnosis of NAFLD/MAFLD and liver fibrosis: Triglyceride glucose index-related parameters.
    Xue Y; Xu J; Li M; Gao Y
    Front Endocrinol (Lausanne); 2022; 13():951689. PubMed ID: 36120429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
    Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
    BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.
    Chen LD; Huang JF; Chen QS; Lin GF; Zeng HX; Lin XF; Lin XJ; Lin L; Lin QC
    Chin Med J (Engl); 2019 Nov; 132(22):2670-2676. PubMed ID: 31765354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of a clinical and laboratory-based nomogram to predict nonalcoholic fatty liver disease.
    Cen C; Wang W; Yu S; Tang X; Liu J; Liu Y; Zhou L; Yu J; Zheng S
    Hepatol Int; 2020 Sep; 14(5):808-816. PubMed ID: 32572817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the diagnostic performance of twelve noninvasive scores of metabolic dysfunction-associated fatty liver disease.
    Zou H; Ma X; Zhang F; Xie Y
    Lipids Health Dis; 2023 Sep; 22(1):145. PubMed ID: 37674196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.
    Zelber-Sagi S; Webb M; Assy N; Blendis L; Yeshua H; Leshno M; Ratziu V; Halpern Z; Oren R; Santo E
    World J Gastroenterol; 2013 Jan; 19(1):57-64. PubMed ID: 23326163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study.
    Koehler EM; Schouten JN; Hansen BE; Hofman A; Stricker BH; Janssen HL
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1201-4. PubMed ID: 23353640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese.
    Huang X; Xu M; Chen Y; Peng K; Huang Y; Wang P; Ding L; Lin L; Xu Y; Chen Y; Lu J; Wang W; Bi Y; Ning G
    Medicine (Baltimore); 2015 Oct; 94(40):e1682. PubMed ID: 26448014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender Differences in the Relationships among Metabolic Syndrome and Various Obesity-Related Indices with Nonalcoholic Fatty Liver Disease in a Taiwanese Population.
    Lin IT; Lee MY; Wang CW; Wu DW; Chen SC
    Int J Environ Res Public Health; 2021 Jan; 18(3):. PubMed ID: 33498329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.